Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
retina
Biotech
Boehringer inks another eye disease deal, this time with Palatin
Boehringer has inked a deal with Palatin Technologies worth up to $327 million biobucks to develop new retinal disease therapies.
Gabrielle Masson
Aug 18, 2025 10:30am
Atsena gene therapy hits safety goals, closes retinal splits
May 19, 2025 12:59pm
Regeneron snaps up eye biotech, snaring science but not staff
Jan 2, 2025 3:58pm
Atsena downsizes to funnel money toward new capsid program
Oct 5, 2023 1:47pm
Zeiss, Boehringer eye retinal disease-focused predictive AI pact
Oct 2, 2023 1:00pm
Cash-strapped eye disease biotech halves portfolio
Aug 8, 2023 2:36pm
